Enliven Therapeutics Inc

ELVN remains in a Stage 2 advancing regime with a confirmed Momentum Breakout signaling strong demand overcoming prior supply. The medium-term bias is bullish, supported by the advancing stage, rising EMAs, and constructive volume; however, the stock is extreme overbought and extended above its 9/20/50 EMAs. Short-term timing is unfavorable for fresh entry, so execution is deferred. Optimal participation comes on a pullback into the rising EMA zone and prior resistance area. Key risks include overbought exhaustion, potential failure to follow through on the breakout, and a Stage 2→3 transition if supply reemerges.

• ↑61% major molecular response at 24 weeks in Phase 1 ENABLE trial raises approval probability to 70%.
• ↑Median price targets from H.C. Wainwright ($65) and Jones Trading ($70) imply ~21% upside from $51.09.
• ↓Profitability score of –2.67 and negative earnings yield (–0.80) point to overvaluation risk.